Montelukast Synthon

Montelukast, the active ingredient in Montelukast Synthon, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for the maintenance treatment of asthma, for prevention of exercise‑induced bronchoconstriction, and for relief of symptoms of seasonal allergic rhinitis in both adults and children.

GNH USA supplies Montelukast Synthon as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality control, batch release testing, and provides regulatory documentation to support international distribution.

Montelukast acts on the leukotriene pathway to manage several respiratory and allergic conditions.

- Asthma: improves long‑term control and reduces frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate head discomfort. - Abdominal pain: transient stomach discomfort. - Cough: occasional dry cough. - Nausea: mild queasiness. - Diarrhea: loose stools. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria or angioedema. - Mood changes: depression, anxiety or suicidal ideation. - Liver enzyme elevations: increased ALT or AST levels.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use. - Assess liver function: monitor hepatic enzymes in patients with liver disease. - Review psychiatric history: observe for mood alterations or suicidal thoughts. - Evaluate drug interactions: avoid concomitant use with strong CYP3A4 inhibitors without monitoring. - Use caution in children: adjust dosing according to age and weight as per prescriber guidance. - Pregnancy and lactation: discuss potential risks with the prescriber; data are limited. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Montelukast may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase montelukast plasma levels, raising risk of adverse effects. - Phenobarbital or rifampin: can reduce montelukast concentrations, diminishing therapeutic benefit.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): may potentiate neuropsychiatric side effects. - Warfarin: occasional reports of altered INR; monitor coagulation parameters. - Beta‑agonists: concurrent use may mask bronchospasm symptoms; monitor respiratory status.